Alejandra Perez

Associate Professor of Clinical and Director, Braman Family Breast Cancer Institute at Plantation

  • 2549 Citations

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Alejandra Perez is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 2549 Citations
  • 14 Article

Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from BOLERO-2

Hortobagyi, G. N., Chen, D., Piccart, M., Rugo, H. S., Burris, H. A., Pritchard, K. I., Campone, M., Noguchi, S., Perez, A., Deleu, I., Shtivelband, M., Masuda, N., Dakhil, S., Anderson, I., Robinson, D. M., He, W., Garg, A., McDonald, E. R., Bitter, H., Huang, A. & 5 others, Taran, T., Bachelot, T., Lebrun, F., Lebwohl, D. & Baselga, J., Feb 10 2016, In : Journal of Clinical Oncology. 34, 5, p. 419-426 8 p.

Research output: Contribution to journalArticle

  • 110 Scopus citations

    Everolimus plus exemestane for hormonereceptor- positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2

    Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., Burris, H. A., Provencher, L., Neven, P., Gnant, M., Shtivelband, M., Wu, C., Fan, J., Feng, W., Taran, T. & Baselga, J., Dec 1 2014, In : Annals of Oncology. 25, 12, p. 2357-2362 6 p.

    Research output: Contribution to journalArticle

  • 285 Scopus citations

    Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2

    Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-hashimy, M., Taran, T. & Burris, H. A., Apr 2014, In : Annals of Oncology. 25, 4, p. 808-815 8 p., mdu009.

    Research output: Contribution to journalArticle

  • 94 Scopus citations

    Anopen-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer

    Esteva, F. J., Franco, S. X., Hagan, M. K., Brewster, A. M., Somer, R. A., Williams, W., Florance, A. M., Turner, S., Stein, S. & Perez, A., Jul 3 2013, In : Oncologist. 18, 6, p. 661-666 6 p.

    Research output: Contribution to journalArticle

  • 15 Scopus citations

    Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

    Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., Beck, J. T., Ito, Y., Yardley, D., Deleu, I., Perez, A., Bachelot, T., Vittori, L., Xu, Z., Mukhopadhyay, P., Lebwohl, D. & 1 others, Hortobagyi, G. N., Feb 9 2012, In : New England Journal of Medicine. 366, 6, p. 520-529 10 p.

    Research output: Contribution to journalArticle

  • 1789 Scopus citations